Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Curevac Manufacturing GmbH manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company is currently responding to 5 pending office actions. These matters are distributed across 4 distinct examiners, which indicates a broad spread of scrutiny for a portfolio of this size. This variety in examiners requires a strategy that accounts for different individual perspectives on pharmaceutical and biotechnological patentability.
The prosecution activity is spread across 4 distinct art units. This suggests that the company's innovations touch upon several different technical sub-specialties within the Biotechnology & Pharmaceuticals field. With 5 pending office actions occurring in these units, the portfolio faces a diverse set of institutional standards and review processes, making it essential for practitioners to adapt their arguments to the specific requirements of each unit.
NGUYEN, QUANG is the busiest examiner for this applicant, currently overseeing 2 busiest examiner pending office actions. While there are 4 distinct examiners involved in the portfolio, the 2 busiest examiner pending office actions assigned to NGUYEN, QUANG represent the highest concentration of the company's current challenges. Success in these specific matters will be a major factor in the overall advancement of the company's intellectual property goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 2 | 37.9% | +52.6% |
| BAKSHI, PANCHAM | 1 | 76.7% | +30.2% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
| ADAMS, MICHELLE | 1 | 58.8% | +40.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | ADAMS, MICHELLE | 42d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | ADAMS, MICHELLE | 42d overdue |
| 19363455 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | BAKSHI, PANCHAM | — |
| 18582620 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | DACE DENITO, ALEXANDRA GERALDINE | — |
| 17932026 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | NGUYEN, QUANG | — |
| 15750745 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | NGUYEN, QUANG | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1623 | 1 |
| 1636 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19363455 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | BAKSHI, PANCHAM | 1623 | §103 | Non-Final OA | — | Pending | Oct 20, 2025 |
| 18582620 | METHODS AND MEANS FOR ENHANCING RNA PRODUCTION | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103§112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18432898 | METHOD FOR ANALYZING BY-PRODUCTS OF RNA IN VITRO TRANSCRIPTION | ADAMS, MICHELLE | 1797 | §103§112 | Final Rejection | 42d overdue | Pending | Feb 05, 2024 |
| 17932026 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | NGUYEN, QUANG | 1631 | §103 | Final Rejection | — | Pending | Sep 14, 2022 |
| 15750745 | METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE | NGUYEN, QUANG | 1631 | §103 | Final Rejection | — | Pending | Feb 06, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCurevac Manufacturing GmbH has 5 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Quang Nguyen has the most, with 2 of Curevac Manufacturing GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
